MB
INSM icon

MPM BioImpact’s Insmed INSM Stock Holding History

MPM BioImpact’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-389,611
Closed -$26.9M – 48
2024
Q4 		$26.9M Sell
389,611
-225,780
-37% -$16.3M 3.82% 4
2024
Q3 		$44.9M Hold
615,391
– – 6.74% 2
2024
Q2 		$41.2M Buy
615,391
+84,597
+16% +$3.28M 6.41% 2
2024
Q1 		$14.4M Buy
530,794
+2,644
+0.5% +$74K 2.32% 14
2023
Q4 		$16.4M Buy
528,150
+692
+0.1% +$17.9K 3.83% 10
2023
Q3 		$13.3M Sell
527,458
-2,285
-0.4% -$52.3K 3.56% 10
2023
Q2 		$11.2M Buy
529,743
+130,551
+33% +$2.48M 2.25% 15
2023
Q1 		$6.81M Sell
399,192
-11,271
-3% -$219K 1.77% 17
2022
Q4 		$8.2M Buy
+410,463
New +$7.93M 2.13% 13

Other funds holding INSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

MPM BioImpact's INSM Position: Q1 2025 in Review

MPM BioImpact sold out of Insmed (INSM) in Q1 2025, closing a stake of 389,611 shares — an estimated $26.9M sold.

MPM BioImpact first reported a position in INSM in Q4 2022 and held it in 9 quarters. The position peaked at $44.9M in Q3 2024. 441 funds tracked by Wall St. Rank hold INSM as of Q1 2025.

  • MPM BioImpact reported no remaining Insmed position as of Q1 2025 after selling out during the quarter.
  • MPM BioImpact sold 389,611 Insmed shares in Q1 2025, an estimated $26.9M.
  • MPM BioImpact first reported a position in Insmed in Q4 2022 and held it in 9 quarters.
  • MPM BioImpact's Insmed position peaked at $44.9M in Q3 2024.
  • 441 funds tracked by Wall St. Rank held Insmed as of Q1 2025.

Based on MPM BioImpact's 13F filing for Q1 2025, filed 15 May 2025.